| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/18/2011 | CN101164619B Pyritinol injection with special purpose solvent |
| 05/18/2011 | CN101015527B Dropping pills preparation |
| 05/18/2011 | CN101014320B Composition of treatment of endobronchial infections |
| 05/17/2011 | US7943757 RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA) |
| 05/17/2011 | US7943644 Stabilization of iodine-containing biocides by means of special azole compounds |
| 05/17/2011 | US7943604 Method of treating human skin and a skin care composition for use in such a method |
| 05/17/2011 | US7943595 Polysaccharides with antithrombotic activity comprising at least one covalent bond with biotin or a biotin derivative |
| 05/17/2011 | US7943586 Antineoplastic agents targeted via glut transporters |
| 05/17/2011 | US7943581 Cell penetrating peptides for intracellular delivery of molecules |
| 05/17/2011 | US7943575 Sustained release drug formulations containing a carrier peptide |
| 05/17/2011 | US7943569 Extracellular protease-activated prodrug comprising a hydrophilic matrix having a therapeutic agent linked thereto via an extracellular protease substrate peptide; e.g. cisplatin conjugated to carboxy groups of an oligopeptide matrix metalloprotease substrate's aspartic acid unit; tissue-targeted therapy |
| 05/17/2011 | US7943559 Cyclopropanated macrocyclic ketones and lactones |
| 05/17/2011 | US7943178 Methods and compositions for delivering peptides |
| 05/17/2011 | US7943176 Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient |
| 05/17/2011 | US7943170 immediate release phase and a sustained release phase of paracetamol, which has a unique in vitro dissolution profile; suitable for treating both acute pain such as dental pain or headache and chronic pain, such as the pain associated with arthritis. |
| 05/17/2011 | US7943164 Contains quercetin, myricetin and chlorogenic acid; weight loss and weight control; inhibiting glucose absorption in the gut, enhancing glucose absorption by muscle tissue, inhibiting carbohydrate transport, inhibiting glucose/fat storage and inhibiting the manufacture of glucose by the liver |
| 05/17/2011 | US7943163 Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes |
| 05/17/2011 | US7943155 Self-reversible reverse microlatex process for preparing it and cosmetic and industrial uses thereof |
| 05/17/2011 | US7943144 Herpes simplex virus complex |
| 05/17/2011 | CA2490157C Self-emulsifying formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability and/or reduced food effect |
| 05/17/2011 | CA2479919C Powder formulations suitable for inhalation |
| 05/17/2011 | CA2479735C Fast dissolving dosage forms having reduced friability |
| 05/17/2011 | CA2423358C Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers |
| 05/17/2011 | CA2422580C Selfemulsifiable formulation having enhanced bioabsorption and immunosuppression activities |
| 05/17/2011 | CA2420597C Milled particles |
| 05/17/2011 | CA2411642C Use of ingenanes for the activation of latent virus infection |
| 05/17/2011 | CA2401385C Protein matrix materials, devices and methods of making and using thereof |
| 05/17/2011 | CA2391923C Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/17/2011 | CA2376339C Morphine sulphate microgranules, method for preparing same and compositions containing same |
| 05/17/2011 | CA2114267C Use of oxidase inhibitor with dextromethorphan to treat intractable coughing and dermatitis |
| 05/12/2011 | WO2011057266A2 Emulsion template method to form small particles of hydrophobic agents with surface enriched hydrophilicity by ultra rapid freezing |
| 05/12/2011 | WO2011057225A2 Self-assembled particles from zwitterionic polymers and related methods |
| 05/12/2011 | WO2011057224A2 Zwitterionic polymer bioconjugates and related methods |
| 05/12/2011 | WO2011057219A2 Crosslinked zwitterionic hydrogels |
| 05/12/2011 | WO2011057180A2 Compositions of apatite and methods of use |
| 05/12/2011 | WO2011057133A1 Fragmented hydrogels |
| 05/12/2011 | WO2011057131A1 Polysaccharide based hydrogels |
| 05/12/2011 | WO2011057108A1 Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| 05/12/2011 | WO2011057020A1 Activity generating delivery molecules |
| 05/12/2011 | WO2011056785A2 Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| 05/12/2011 | WO2011056775A2 Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
| 05/12/2011 | WO2011056702A2 Fast dissolving/disintegrating coating compositions |
| 05/12/2011 | WO2011056653A2 Clonidine formulations having antimicrobial properties |
| 05/12/2011 | WO2011056288A1 Functionalized nanomaterials for dermal decorporation, chelation, therapy, and sorbent dialysis of radiounuclides and toxins |
| 05/12/2011 | WO2011056116A1 Composition for promoting wound healing |
| 05/12/2011 | WO2011056115A1 Lipid layer forming composition for administration onto a surface of a living organism |
| 05/12/2011 | WO2011055708A1 Isopropyl methyl phenol-containing liquid composition for oral cavity |
| 05/12/2011 | WO2011055385A1 Modified release formulation of lacosamide |
| 05/12/2011 | WO2011055324A1 Synhetic immunogenic glycoconjugate for melanoma immunotherapy |
| 05/12/2011 | WO2011055269A1 Delivery carrier |
| 05/12/2011 | WO2011055047A1 Aqueous composition comprising gold nanoparticles, serum albumin and/or collagen for laser tissue welding |
| 05/12/2011 | WO2011054837A2 Bifunctional prodrugs and drugs |
| 05/12/2011 | WO2011054699A1 Use of biocompatible compositions and materials polymerized therefrom for inhibiting angiogenesis |
| 05/12/2011 | WO2011054112A1 Antibodies that specifically block the biological activity of kidney associated antigen 1 |
| 05/12/2011 | WO2011054087A1 Stable pharmaceutical formulations comprising lubiprostone |
| 05/12/2011 | WO2011012850A9 Glycopolysialylation of non-blood coagulation proteins |
| 05/12/2011 | WO2011011347A3 Functionalization of silk material by avidin-biotin interaction |
| 05/12/2011 | WO2011008823A3 Peptide-mediated non-covalent delivery of active agents across the blood brain barrier |
| 05/12/2011 | WO2011005853A3 Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome |
| 05/12/2011 | WO2010148012A3 Hemostatic material and delivery device |
| 05/12/2011 | WO2010138393A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 05/12/2011 | WO2010138389A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 05/12/2011 | WO2010138387A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 05/12/2011 | WO2010100200A3 Lyophilised antibody formulation |
| 05/12/2011 | WO2010079037A3 Aqueous dispersion comprising pesticide particles and an amphiphile |
| 05/12/2011 | WO2010017273A3 Tigecycline formulations |
| 05/12/2011 | US20110112618 Drug eluting composite |
| 05/12/2011 | US20110112259 Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
| 05/12/2011 | US20110112115 Polymeric microemulsions |
| 05/12/2011 | US20110111493 Compositions and Methods For Inhibiting Expression Of A Target Gene |
| 05/12/2011 | US20110111061 Compositions and Methods for the Treatment of Skeletal Metastatic Lesions and Fractures |
| 05/12/2011 | US20110111044 Nanoparticle compositions for nucleic acids delivery system |
| 05/12/2011 | US20110111028 Composition and Methods For Repair of Connective Tissue |
| 05/12/2011 | US20110111010 Method and Composition for Burned Skin |
| 05/12/2011 | US20110110970 Chimeric vaccines |
| 05/12/2011 | US20110110952 Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer |
| 05/12/2011 | CA2817014A1 Activity generating delivery molecules |
| 05/12/2011 | CA2816437A1 Antibodies that specifically block the biological activity of kidney associated antigen 1 |
| 05/12/2011 | CA2780294A1 Polysaccharide based hydrogels |
| 05/12/2011 | CA2780268A1 Ophthalmic formulations containing substituted gamma lactams and methods for use thereof |
| 05/12/2011 | CA2780163A1 Method for treating heart failure with stresscopin-like peptides |
| 05/12/2011 | CA2779736A1 Stable pharmaceutical formulations comprising lubiprostone |
| 05/12/2011 | CA2779433A1 Composition for promoting wound healing |
| 05/12/2011 | CA2779432A1 Lipid layer forming composition for administration onto a surface of a living organism |
| 05/12/2011 | CA2779005A1 Delivery carrier |
| 05/12/2011 | CA2778003A1 Stable thickener formulations |
| 05/12/2011 | CA2773353A1 Oligomer-calcimimetic conjugates and related compounds |
| 05/11/2011 | EP2319894A1 Novel lipid dipeptide and gel |
| 05/11/2011 | EP2319858A1 Aqueous suspensions of ciclesonide for nebulisation |
| 05/11/2011 | EP2319826A1 Succinate salt of O-desmethyl-venlafaxin |
| 05/11/2011 | EP2319585A1 Pharmaceutical products and compositions comprising salmeterol, fluticasone and ipratropium or tiotropium |
| 05/11/2011 | EP2319584A1 Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium |
| 05/11/2011 | EP2319583A1 Pharmaceutical products and compositions comprising salmeterol, budesonide and ipratropium |
| 05/11/2011 | EP2319582A1 Pharmaceutical products and compositions comprising formoterol, budesonide and tiotropium or oxitropium |
| 05/11/2011 | EP2319542A2 Segmented degradable polymers and conjugates made therefrom |
| 05/11/2011 | EP2319541A1 Factor VII or VIIA-like conjugates |
| 05/11/2011 | EP2319540A1 Sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/11/2011 | EP2319519A1 Composition for inhibiting expression of target gene |
| 05/11/2011 | EP2319518A1 Use of CO-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases |
| 05/11/2011 | EP2319517A1 Use of prodrugs for ocular intravitreous administration |